ABVC | ABVC BioPharma, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.5300 - 0.5565
52 Week Range	0.4050 - 1.7300
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	56,293
Average Volume	249,296
Shares Outstanding	12,975,500
Market Cap	7,022,341
Sector	Healthcare
Industry	Biotechnology
IPO Date	2004-11-10

Valuation
Profitability
Growth
Health
P/E Ratio	-0.67
Forward P/E Ratio	N/A
EPS	-0.81
1YR Price Target	20.20
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	16
Country	USA
Website	ABVC

ABVC BioPharma licenses promising medical research conducted in the Asia-Pacific region and enlists top-ranked principal investigators in the United States to conduct Phase II clinical trials. We specialize in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes that represent enormous commercial potential.

ABVC's peers: ALRN, BCDA, CRDL, INDP, KTTA, BTTX, FBRX, EVLO, APTX, MGTA, ARDS, AKTX, ADTX, ACST, RNXT, ANEB, SABS, MNPR, ELDN, NTRB, QNRX, LGVN, VRAX, NNVC

*Chart delayed

Analyzing fundamentals for ABVC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see ABVC Fundamentals page.

Watching at ABVC technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ABVC Technicals page.